Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCellCentric Ltd.
About this trial
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.
Eligibility criteria
Qualifiers
Male or female ≥18 years of age
Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy
Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2
Adequate hematological, renal and hepatic function
Disqualifiers
Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest; any antibody based therapy within 30 days
Prior treatment with p300/CBP bromodomain inhibitors
Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide)
Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment
Trial design
Treatments tested in this trial
- Inobrodib
- Pomalidomide
- Dexamethasone
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov